Giulia Pasello, Associate Professor in Oncology at the University of Padova, shared a post on LinkedIn :
“Today the results of the COMPEL study in EGFR mutant NSCLC have been presented at the 2025 WCLC in Barcelona.
Patients’ heterogeneity requires several weapons in first and second line treatment, and COMPEL trial made a further step towards the personalized strategy for every single patient. Thanks to the patients, their caregivers, the coinvestigators and the study team for being part of this.
Osimertinib in combination with chemotherapy was associated with longer PFS, OS and non CNS PFS in patients with extracranial disease progression to osimertinib.
Listen to the voice of patients, discuss and empower them in the optimal clinical decision!”
Read Part 1, Part 2 and Part 3 of WCLC25 Highlights on OncoDaily.
